NEJM February 2026 Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

monoclonal antibody designed to block a protein called APRIL that fuels the progression of IgA nephropathy. By neutralizing this key driver, the drug aims to reduce the production of harmful antibodies that damage the kidneys' filtering units. The interim results from this randomized, placebo-controlled trial demonstrate that patients receiving the treatment experienced a significant reduction in proteinuria—a critical marker of kidney stress—compared to those receiving a placebo. Ultimately, the data suggests that sibeprenlimab is a safe and potent intervention capable of drastically lowering the levels of pathogenic proteins while maintaining a side-effect profile comparable to the control group.